SEPNSepterna, Inc.
Pharmaceutical Preparations
- Revenue
- $46M
- 4175% YoY
- Operating margin
- -148.6%
- 98% YoY
- EBITDA
- −$67M
- 16% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired18% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $151K | $1M | $46M | 4175% |
| Operating income | $2M | −$81M | −$68M | 15% |
| Net income | $4M | −$72M | −$49M | 32% |
| Operating cash flow | −$39M | −$67M | $110M | 263% |
| Capex | $3M | $2M | $518K | 75% |
| Stock-based comp | $2M | $3M | $8M | 169% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $150K · 2
- Net
- −$150K
Pay vs performance
No pay-versus-performance disclosure yet.